Acupuncture for Cancer Related Pain: Protocol for a Pragmatic Randomised Wait-List Controlled Trial. (December 2020)

• Record Type: Journal Article
• Authors: Zhao, Qi; Zheng, Suyang; Delaney, Geoff P.; Moylan, Eugene; Agar, Meera R.; Koh, Eng-Siew; Lai, Hezheng; Birling, Yoann; Zhang, George Shengxi; Wang, Kang; Ma, Yong; Zhu, Xiaoshu
• Is Part Of: Integrative cancer therapies. Volume 19(2020)
• Publication Date: 2020-12
• Subjects: acupuncture -- cancer related pain -- pragmatic -- clinical trial -- complementary and alternative medicine; Cancer -- Alternative treatment -- Periodicals; 616.99406
• DOI: 10.1177/1534735420976579
• Languages: English
• ISSNs: 1534-7354

Abstract

Background: Acupuncture has been proved effective for cancer related pain (CRP) in China, America and some other countries. However, there is relative lack of evidence to support the use of acupuncture for CRP in Australia. Objectives: To assess the effectiveness and safety of acupuncture for management of CRP in a real-world setting and to understand cancer patients' experience of undergoing acupuncture for CRP. Methods: A pragmatic randomised controlled trial will be conducted in South Western Sydney Local Health District (SWSLHD) in NSW, Australia. Adults with cancer related pain (n = 106) will be randomised in a 1:1 ratio to receive the acupuncture intervention up front versus after a wait list period of 4 weeks. Pain level (by Numerical Rating Scale), analgesic use, auricular acupressure frequency and adverse events will be assessed at baseline, mid-treatment and post-treatment. Expectancy on trial outcome (by Credibility and Expectancy questionnaire) will be assessed at baseline. The perspective of the participants (by an interview) will be recorded after the last intervention. Expected outcomes: We hypothesise that acupuncture will relieve cancer related pain at mid-treatment and post-treatment. We also hypothesise that few adverse events will be provoked by acupuncture. Trial registration: Australia New-Zealand Clinical Trial Registry (ACTRN12620000325909).